Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

BACKGROUND: The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) by 38.3 months after treatment with irinotecan, fluorouracil, and leucovorin (FOLFIRI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jiaqi, Xiao, Desheng, Tan, Chongqing, Zeng, Xiaohui, Hu, Huabin, Zeng, Shan, Jiang, Qin, She, Longjiang, Yao, Linli, Li, Li, Tang, Lanhua, Ma, Jian, Huang, Jin, Shen, Liangfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053788/
https://www.ncbi.nlm.nih.gov/pubmed/32107929
http://dx.doi.org/10.1177/1073274820902271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053788/
https://www.ncbi.nlm.nih.gov/pubmed/32107929
http://dx.doi.org/10.1177/1073274820902271

Ejemplares similares